Beam Therapeutics Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Beam Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $294.94 million for the year ending 2025.

  • Beam Therapeutics Inc. showed an increase of +4.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 692.4%.
  • Historical annual values: Fiscal year 2025: $294.94 million | Fiscal year 2024: $281.97 million | Fiscal year 2023: $435.90 million | Fiscal year 2022: $232.77 million | Fiscal year 2021: $559.99 million | Fiscal year 2020: $162.17 million | Fiscal year 2019: $37.22 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: